BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 6612234)

  • 1. Presenting symptoms, treatment delay and survival in bladder cancer.
    Mommsen S; Aagaard J; Sell A
    Scand J Urol Nephrol; 1983; 17(2):163-7. PubMed ID: 6612234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Bladder Carcinoma in Females: A Clinico-Pathological Assessment.
    Gupta R; Khan SM; Mahajan M; Sharma P; Mahajan A
    Cureus; 2023 May; 15(5):e39753. PubMed ID: 37398730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis.
    Medina-Lara A; Grigore B; Lewis R; Peters J; Price S; Landa P; Robinson S; Neal R; Hamilton W; Spencer AE
    Health Technol Assess; 2020 Nov; 24(66):1-332. PubMed ID: 33252328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial.
    Sell V; Ettala O; Montoya Perez I; Järvinen R; Pekkarinen T; Vaarala M; Seppänen M; Liukkonen T; Marttila T; Aaltomaa S; Kaasinen E; Boström PJ
    World J Urol; 2020 Apr; 38(4):1001-1007. PubMed ID: 31177305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea.
    Shim JS; Seo HK; Ku JH; Jeong BC; Hong B; Kang SH
    Cancer Res Treat; 2019 Jul; 51(3):1064-1072. PubMed ID: 30376708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries.
    Han DS; Zhou W; Seigne JD; Lynch KE; Schroeck FR
    Urology; 2018 Dec; 122():83-88. PubMed ID: 30138684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment.
    Williams SB; Huo J; Dafashy TJ; Ghaffary CK; Baillargeon JG; Morales EE; Kim SP; Kuo YF; Orihuela E; Tyler DS; Freedland SJ; Kamat AM
    Urol Oncol; 2017 Oct; 35(10):602.e1-602.e9. PubMed ID: 28647395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.
    Neal RD; Tharmanathan P; France B; Din NU; Cotton S; Fallon-Ferguson J; Hamilton W; Hendry A; Hendry M; Lewis R; Macleod U; Mitchell ED; Pickett M; Rai T; Shaw K; Stuart N; Tørring ML; Wilkinson C; Williams B; Williams N; Emery J
    Br J Cancer; 2015 Mar; 112 Suppl 1(Suppl 1):S92-107. PubMed ID: 25734382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of bladder cancer in primary care.
    Shephard EA; Stapley S; Neal RD; Rose P; Walter FM; Hamilton WT
    Br J Gen Pract; 2012 Sep; 62(602):e598-604. PubMed ID: 22947580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance measures of the specialty referral process: a systematic review of the literature.
    Guevara JP; Hsu D; Forrest CB
    BMC Health Serv Res; 2011 Jul; 11():168. PubMed ID: 21752285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers.
    Macleod U; Mitchell ED; Burgess C; Macdonald S; Ramirez AJ
    Br J Cancer; 2009 Dec; 101 Suppl 2(Suppl 2):S92-S101. PubMed ID: 19956172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec.
    Fahmy N; Kassouf W; Jeyaganth S; Amin M; Mahmud S; Steinberg J; Tanguay S; Aprikian A
    Can Urol Assoc J; 2008 Apr; 2(2):102-8. PubMed ID: 18542741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of macroscopic haematuria in the emergency department.
    Hicks D; Li CY
    Emerg Med J; 2007 Jun; 24(6):385-90. PubMed ID: 17513531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alarm symptoms in primary care.
    Fox R; Fletcher J
    BMJ; 2007 May; 334(7602):1013-4. PubMed ID: 17510105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How will the two-weeks-wait rule affect delays in management of urological cancers?
    Subramonian KR; Puranik S; Mufti GR
    J R Soc Med; 2003 Aug; 96(8):398-9. PubMed ID: 12893857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice.
    Bruyninckx R; Buntinx F; Aertgeerts B; Van Casteren V
    Br J Gen Pract; 2003 Jan; 53(486):31-5. PubMed ID: 12564274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies.
    Summerton N; Mann S; Rigby AS; Ashley J; Palmer S; Hetherington JW
    Br J Gen Pract; 2002 Apr; 52(477):284-9. PubMed ID: 11942444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The haematuria clinic--referral patterns in Northern Ireland.
    Ho ET; Johnston SR; Keane PF
    Ulster Med J; 1998 May; 67(1):25-8. PubMed ID: 9652195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The haematuria clinic.
    Marazzi P; Gabriel R
    BMJ; 1994 Feb; 308(6925):356. PubMed ID: 8124142
    [No Abstract]   [Full Text] [Related]  

  • 20. Delays in diagnosing and treating bladder cancer.
    Stower MJ
    Br Med J (Clin Res Ed); 1988 Apr; 296(6631):1228-9. PubMed ID: 3133024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.